Treatment With REBYOTA^™

Access information about REBYOTA administration, patient experiences, and more.

One dose one visit

REBYOTA is a single-dose treatment—delivered at your doctor’s office, and is administered within minutes¹
REBYOTA is delivered rectally to your gut microbiome, where it’s needed
REBYOTA requires no bowel prep, anesthesia, or colonoscopy

This is Patricia’s Story

For me, it was one dose and one visit, and that was it. I drove myself home and I was fine. Since treatment, I haven’t had any recurrence of C. diff.

Watch Patricia’s Story

Most common side effects may include stomach pain, diarrhea, bloating, gas, and nausea.

For more information, please talk to your doctor and see full Prescribing Information. Patricia was compensated for her time. Individual results may vary.

Image of Patricia, clinical study patient — Patricia, Clinical Study Patient

Learn more about C. diff infection and preventing its recurrence with REBYOTA.

Download Brochure

Your REBYOTA Experience

Watch as a nurse shows you what to expect before, during, and after treatment with REBYOTA.

REBYOTA is available by prescription only. Talk to your doctor to find out if REBYOTA is right for you.

Candace, RN, CCRP, was compensated for her time.

Getting ready for treatment with REBYOTA¹

BEFORE
TREATMENT

No preparation is required

You should complete your antibiotic prescription 1 to 3 days before your REBYOTA treatment
No bowel prep is required

DURING
TREATMENT

Administration happens
within minutes

Anesthesia or colonoscopy are not necessary
The doctor or nurse will place you in the preferred position for the administration
You may be asked to remain in place for about 15 minutes to minimize any cramping that may occur

AFTER
TREATMENT

You can return home

Follow your doctor’s instruction

Talk to your doctor…

If you have diarrhea 3 or more times a day for 2 days in a row
Before taking antibiotics
for any reason for 8 weeks after treatment with REBYOTA

This is Marty’s Story

After REBYOTA, my symptoms never came back. I’ve had no recurrences.

Watch Marty’s Story

Most common side effects may include stomach pain, diarrhea, bloating, gas, and nausea.

For more information, please talk to your doctor and see full Prescribing Information. Marty was compensated for his time. Individual results may vary.

Image of Marty, clinical study patient — Marty, Clinical Study Patient

Sign up for more information

Receive additional information and resources to help you through your C. diff infection journey.

First Name*(Required)

Last Name*(Required)

Email Address*(Required)

Phone Number

What’s your experience with C. diff infection?*(Required)

What’s your experience with C. diff infection?*

I currently have a C. diff infection

I had a C. diff infection within the last year

I am a C. diff patient caregiver

I’m interested in learning more about C. diff

*Required field.

Consent(Required)

I CONSENT(Required)

By providing the information requested, I am giving Ferring permission to store and use the information that I have provided. I understand and agree that my information will be used by Ferring (or companies working on Ferring’s behalf) to contact me by telephone, email, or mail to provide me with information that may be of interest to me or to invite me to participate in research, educational, and marketing initiatives. I understand that my information will be treated as described in Ferring’s Privacy Notice, which provides details about my privacy rights. Also, I understand that I may opt out of the database at any time by making the request at Data Subject Form or by calling 1-888-FERRING, Monday through Friday, 8 _AM to 7 _PM ET to speak to a representative or leave a voicemail. This statement may be updated from time to time.

References

REBYOTA. Prescribing Information. Parsippany, NJ: Ferring Pharmaceuticals Inc; 2022.

Please see Important Safety Information and full Prescribing Information

INDICATION

REBYOTA (fecal microbiota, live – jslm) is indicated for the prevention of recurrence of Clostridioides difficile (C. diff) infection in individuals
18 years of age and older, following antibiotic treatment for recurrent C. diff infection.
Limitation of Use
REBYOTA is not indicated for the treatment of C. diff infection.

Important Safety Information

You should not receive REBYOTA if you have a history of a severe allergic reaction (e.g., anaphylaxis) to REBYOTA or any of its components.
You should report to your doctor any infection you think you may have acquired after administration.
REBYOTA may contain food allergens.
Most common side effects may include stomach pain (8.9%), diarrhea (7.2%), bloating (3.9%), gas (3.3%), and nausea (3.3%).
REBYOTA has not been studied in patients below 18 years of age.
Clinical studies did not determine if adults 65 years of age and older responded differently than younger adults.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch or call 1-800-332-1088.

Please click to see the full Prescribing Information

You are leaving REBYOTA.com

The link you have selected will direct you to a site or resource outside of our website.
Thank you.

Okay

Treatment With REBYOTA™